Inside the FDA office that oversees gene therapies, some staff believed Sarepta's gene therapy for Duchenne should be rejected. www.statnews.com Check out last month's top stories. If you like what you see, join the STAT+ community today — and enjoy 25% off your first year. KRISTOFFER TRIPPLAAR/SIPA VIA AP FDA staff leaned toward rejecting Sarepta gene therapy before top official intervened by Adam Feuerstein and Jason Mast READ MORE MOLLY FERGUSON FOR STAT Mindpath seemed like a success story for private equity in mental health. Now, it's a cautionary tale by Olivia Goldhill READ MORE MADDIE MCGARVEY FOR STAT A bellwether moment: Once a distant dream, gene therapy for Duchenne nears historic decision by Jason Mast and Adam Feuerstein READ MORE MORE TOP STORIES Early findings in gene therapy death suggest CRISPR was not the cause by Jason MastWith weight loss drug ads, telehealth companies wade into a regulatory gray area by Mohana RavindranathPear Therapeutics dreamt of huge revenues and 'commercial scale.' It never came close by Mario AguilarNew mega-deal highlights Geisinger's fall, and raises concerns about where Kaiser is going next by Bob HermanDigital health pioneer Pear Therapeutics files for bankruptcy by Mario Aguilar Research misconduct allegations put Stanford's president — and science — under an uncomfortable spotlight by Jonathan WosenCongress is launching a tobacco harm reduction caucus. Its biggest supporter so far? Philip Morris by Nicholas Florko SUBSCRIBE Friday, May 5, 2023 1 Exchange Place, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us
.jpeg?width=1094&height=730&upscale=true&name=AP_18056286679499%20(1).jpeg)
No comments